How oGVHD Is Diagnosed: Building the Clinical Picture
Ocular graft-versus-host disease can be difficult to diagnose for the same reason it can be difficult to live with: it does not present in exactly the same way in every patient.
One person may develop profound tear deficiency after allogeneic hematopoietic stem cell transplantation. Another may have more prominent inflammation, corneal staining, eyelid disease, or meibomian gland dysfunction. Some patients experience severe symptoms even when the visible findings appear relatively modest. Others may have substantial ocular surface damage before their symptoms fully reflect its severity.
That variability means there is no single test that can answer the question, “Does this patient have oGVHD?”
Instead, diagnosis is built from a clinical picture.
The transplant history provides the essential context. Persistent or newly developing dryness, burning, grittiness, redness, light sensitivity, pain, or fluctuating vision takes on different significance in someone who has undergone an allogeneic transplant, particularly when chronic graft-versus-host disease is present elsewhere in the body.
From there, clinicians evaluate the ocular surface itself. Examination may include the cornea, conjunctiva, eyelids, meibomian glands, tear film, and areas of possible scarring or epithelial injury. Tear production can be measured with tests such as the Schirmer test, while diagnostic dyes can reveal areas of ocular surface damage that may not otherwise be obvious. Tear-film stability, visual function, and the patient’s description of symptoms add further pieces to the picture.
Several diagnostic and severity frameworks have been developed because the field has long recognized that oGVHD cannot be captured by one measurement. The National Institutes of Health criteria, for example, incorporate symptoms and the amount of supportive eye care a patient requires. International consensus approaches have combined symptoms with objective findings such as tear production, corneal staining, and conjunctival changes.
These frameworks are useful, but they also reveal something fundamental about the disease. oGVHD is not one abnormal number. It is a disorder involving an interconnected ocular surface system, and different parts of that system may be affected to different degrees.
That is why diagnosis requires both measurement and interpretation. A low tear-production result matters, but so does the condition of the cornea. Surface staining matters, but so does the patient’s ability to function comfortably. Transplant history matters because it changes the meaning of all those findings.
For patients and advocates, this is an important distinction. An eye examination after transplant is not simply a search for “dry eye.” It is an effort to determine whether the ocular surface is showing evidence of a transplant-related immune disease and, if so, how that disease is affecting the tissues responsible for maintaining comfort and vision.
In oGVHD, the diagnosis comes from understanding the whole eye in the context of the whole patient.
This article is for educational purposes only and is not medical advice.
Sources:
- Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/ - Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full - Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
